Education
About Us
Working with TipRanks
Follow Us
Replimune Group Inc (REPL)
NASDAQ:REPL
REPL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.93 - $17.00
Previous CloseN/A
Volume95.41K
Average Volume (3M)1.36M
Market Cap
$737.72M
Enterprise Value$166.04M
Total Cash (Recent Filing)$483.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Jul 31, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding77,086,750
10 Day Avg. Volume1,823,891
30 Day Avg. Volume1,355,135
Financial Highlights & Ratios
PEG Ratio4.83
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market Cap0.23
Enterprise Value/Revenue13.69
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.18
Forecast
1Y Price Target
$19.20Price Target Upside98.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Replimune Group News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessRP1 + Opdivo achieved an objective response rate of 33.6% in anti-PD1 failed melanoma patients, which is significantly higher than what would be expected with an anti-PD1 agent alone.
Financial StabilityThe company has a cash runway of $536.5M that extends into 4Q26, covering the commercial launch of RP1 and further developments of RP2.
Regulatory ProgressThe FDA has accepted Replimune Group's BLA for RP1 and granted priority review, with no advisory committee planned, indicating confidence in the drug's potential approval.
Bears Say
Market CompetitionInvestor interest is focused on the potential FDA approval of RP1 in combination with Opdivo for the treatment of advanced melanoma, indicating competitive pressure.
Regulatory UncertaintyThe upcoming FDA decision on RP1’s BLA filing is seen as the next key catalyst for the stock, highlighting the potential for significant market impact.
Research And Development RisksRP2 is being developed in uveal melanoma and hepatocellular carcinoma, with new trials enrolling patients and expanding its research scope, which presents risks and uncertainties.
Ownership Overview
Currently, No data available
---
REPL FAQ
What was Replimune Group Inc’s price range in the past 12 months?
Replimune Group Inc lowest stock price was $4.93 and its highest was $17.00 in the past 12 months.
What is Replimune Group Inc’s market cap?
Replimune Group Inc’s market cap is $737.72M.
When is Replimune Group Inc’s upcoming earnings report date?
Replimune Group Inc’s upcoming earnings report date is Jul 31, 2025 which is in 55 days.
How were Replimune Group Inc’s earnings last quarter?
Replimune Group Inc released its earnings results on May 22, 2025. The company reported -$0.82 earnings per share for the quarter, missing the consensus estimate of -$0.717 by -$0.103.
Is Replimune Group Inc overvalued?
According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued.
Does Replimune Group Inc pay dividends?
Replimune Group Inc does not currently pay dividends.
What is Replimune Group Inc’s EPS estimate?
Replimune Group Inc’s EPS estimate is -0.83.
How many shares outstanding does Replimune Group Inc have?
Replimune Group Inc has 77,086,750 shares outstanding.
What happened to Replimune Group Inc’s price movement after its last earnings report?
Replimune Group Inc reported an EPS of -$0.82 in its last earnings report, missing expectations of -$0.717. Following the earnings report the stock price went up 3.546%.
Which hedge fund is a major shareholder of Replimune Group Inc?
Currently, no hedge funds are holding shares in REPL
Replimune Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.20 (98.14% Upside)
$19.20 (98.14% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 13.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $603.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 15.0%
Last 30 Days ▲ 15.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
77.02%
12-Months-Change
Fundamentals
Return on Equity
-62.58%
Trailing 12-Months
Asset Growth
13.04%
Trailing 12-Months
Company Description
Replimune Group Inc
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
REPL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment, emphasizing significant progress towards the approval and launch of RP1 with strong clinical data and a well-prepared commercial strategy. However, increased expenses and losses, along with a lengthy enrollment period for a confirmatory trial, present challenges that need to be addressed.Read More>REPL Stock 12 Month Forecast
Average Price Target
$19.20
▲(98.14%Upside)
Technical Analysis
Chimerix
―
Xencor
―
Rocket Pharmaceuticals
―
Intellia Therapeutics
―
Praxis Precision Medicines
―